S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Warning: Why your IRA could crash on September 21st (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Warning: Why your IRA could crash on September 21st (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Warning: Why your IRA could crash on September 21st (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Warning: Why your IRA could crash on September 21st (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:SRPT

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$109.26
-3.81 (-3.37%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$108.69
$113.42
50-Day Range
$62.69
$113.07
52-Week Range
$61.28
$113.60
Volume
1.02 million shs
Average Volume
922,619 shs
Market Capitalization
$9.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$128.62

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
17.7% Upside
$128.62 Price Target
Short Interest
Healthy
5.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.23mentions of Sarepta Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.86) to ($3.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

346th out of 1,112 stocks

Pharmaceutical Preparations Industry

171st out of 544 stocks

SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $3.81 during trading on Thursday, reaching $109.26. 1,020,438 shares of the stock traded hands, compared to its average volume of 922,619. The company has a quick ratio of 4.14, a current ratio of 4.53 and a debt-to-equity ratio of 1.52. Sarepta Therapeutics has a 52-week low of $61.28 and a 52-week high of $113.60. The company has a 50-day moving average of $80.50 and a 200-day moving average of $77.57.

Analyst Ratings Changes

Several brokerages recently issued reports on SRPT. Royal Bank of Canada lifted their target price on Sarepta Therapeutics from $160.00 to $182.00 and gave the company an "outperform" rating in a research report on Tuesday. Barclays upped their target price on shares of Sarepta Therapeutics from $104.00 to $125.00 in a research note on Wednesday, August 3rd. Credit Suisse Group raised their price target on shares of Sarepta Therapeutics from $90.00 to $93.00 and gave the company a "neutral" rating in a research report on Wednesday, August 3rd. The Goldman Sachs Group reduced their price objective on shares of Sarepta Therapeutics from $181.00 to $155.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. Finally, Needham & Company LLC increased their price objective on shares of Sarepta Therapeutics from $150.00 to $162.00 and gave the company a "buy" rating in a research note on Friday, July 29th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $128.62.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
SRPT June 2023 Options Begin Trading
Sarepta Therapeutics Earnings Preview
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/03/2021
Today
8/11/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$128.62
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+17.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-60.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$8.30 per share

Miscellaneous

Free Float
82,401,000
Market Cap
$9.57 billion
Optionable
Optionable
Beta
1.27














SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2022?

13 brokerages have issued 1-year price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $90.00 to $182.00. On average, they anticipate the company's stock price to reach $128.62 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2022?

Sarepta Therapeutics' stock was trading at $90.05 on January 1st, 2022. Since then, SRPT shares have increased by 21.3% and is now trading at $109.26.
View the best growth stocks for 2022 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($1.86) by $1.26. The biotechnology company had revenue of $189.41 million for the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative net margin of 60.66% and a negative trailing twelve-month return on equity of 67.98%. During the same quarter in the prior year, the company earned ($2.50) earnings per share.

What guidance has Sarepta Therapeutics issued on next quarter's earnings?

Sarepta Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $905.00 million-$920.00 million, compared to the consensus revenue estimate of $899.91 million.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (0.51%), Assenagon Asset Management S.A. (0.51%), Tekla Capital Management LLC (0.24%), Allspring Global Investments Holdings LLC (0.24%), Swiss National Bank (0.22%) and California Public Employees Retirement System (0.19%). Insiders that own company stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $109.26.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $9.57 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.